To study the effectiveness of lower potencies of Galega Officinalis in controlling hyperglycaemia in patients with type 2 diabetes mellitus and to compare it with patients on Metformin.

A Prospective Comparative Open Label Study to Evaluate The Effectiveness of Galega Officinalis in reducing hyperglycaemia in patients with type 2 diabetes mellitus on Metformin therapy - GALEGA - DM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106840

Enrollment

Registered

2026-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Galega Officinalis: Galega Officinalis 6C 3 grain tablet 2 times daily

Q or 1X or 3X 10 drops diluted in 30ml of water 2 times for one-month further repetitions will be done according to fasting blood sugar and HbA1c level Control Intervention1: Metformin 500 mg to 1000

Eligibility

Inclusion criteria

Inclusion criteria: 1)Cases with FBS greater than or equal to 126mg/dl,HbA1c greater than or equal to 6.5 % 2)Age group between 35-70 years of both gender and all socio economic group 3)Patients who have given consent for the study

Exclusion criteria

Exclusion criteria: 1)Patients with uncontrolled hyperglycemia 2)Patients with complications of type 2 diabetes mellitus and severe comorbidities 3)Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
To assess the changes in FBS and HbA1c levels of patients with Type II diabetes mellitus after administering Homoeopathic medicine Galega Officinalis. To study whether the Galega Officinalis in patients with Type II diabetes mellitus is more effective than the patients under Metformin. Timepoint: Changes in the FBS and HbA1C from baseline to 6 months before and after treatment with Galega Officinalis and Metformin	—

Measure

Time frame

To assess the changes in FBS and HbA1c levels of patients with Type II diabetes mellitus after administering Homoeopathic medicine Galega Officinalis. To study whether the Galega Officinalis in patients with Type II diabetes mellitus is more effective than the patients under Metformin. Timepoint: Changes in the FBS and HbA1C from baseline to 6 months before and after treatment with Galega Officinalis and Metformin

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Lakshmi G L

Government Homoeopathic Medical College Thiruvananthapuram

lglhomoeo@gmail.com9446338652

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026